#neurology

A new report says brain imaging is revealing migraine headache subtypes, adding to evidence that the condition is more complex than a single category of severe headache.

Angelini Pharma has agreed to buy Catalyst Pharmaceuticals for $4.1 billion, a move that would add three FDA-approved rare-disease medicines to its neurology portfolio.

A large review published in the Annals of Internal Medicine found that newer migraine treatments can reduce headache days while causing fewer side effects, giving clinicians a clearer picture of which options may work be

The latest annual survey of Alzheimer’s drug development finds a larger and more diverse clinical pipeline, with more trials, more therapeutic approaches, and a declining share of amyloid-targeted programs.

A machine-learning study from VIB and KU Leuven argues that Parkinson’s is not one disease but a family of molecularly distinct disorders, a finding that could reshape how therapies are developed and matched to patients.

Research highlighted by Medical Xpress suggests exercise is one of the most effective ways to slow the progression of Parkinson’s disease, reinforcing its role as more than a general wellness recommendation.

St. Jude researchers report that an antisense oligonucleotide therapy reversed key features of HNRNPH2-related neurodevelopmental disorder in preclinical models, offering mechanistic support for a move toward human study

University of Central Florida researchers report evidence that some movement-related symptoms of Alzheimer's disease may originate outside the brain, a finding that could shift future diagnosis and treatment approaches

A new review says anti-amyloid Alzheimer's treatments are unlikely to deliver clinically meaningful benefits and may raise the risk of brain bleeding and swelling, reopening debate over one of medicine's most contested R

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.

A major new study tracking MS in England from 2000 to 2020 finds that recorded prevalence has more than doubled — but the increase reflects better diagnosis and longer survival rather than an underlying epidemic, painting a complex picture of progress and persistent challenge in one of neurology's most studied diseases.